Targeted Therapies for Castration-Resistant Prostate Cancer

2011 ◽  
Author(s):  
Peter T Scardino
Keyword(s):  
Prostate Cancer ◽  
Targeted Therapies ◽  
Castration Resistant Prostate Cancer ◽  
Castration Resistant

scholarly journals Changing the History of Prostate Cancer with New Targeted Therapies

Biomedicines ◽  
2021 ◽  
Vol 9 (4) ◽  
pp. 392
Author(s):  
Susana Hernando Polo ◽  
Diana Moreno Muñoz ◽  
Adriana Carolina Rosero Rodríguez ◽  
Jorge Silva Ruiz ◽  
Diana Isabel Rosero Rodríguez ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Targeted Therapies ◽  
Synthetic Lethality ◽  
Castration Resistant Prostate Cancer ◽  
Phosphatidylinositol 3 Kinase ◽  
Castration Resistant ◽  
Therapeutic Landscape ◽  
Important Benefit ◽  
History Of ◽  
Repair Genes

The therapeutic landscape of metastatic castration-resistant prostate cancer (mCRPC) is changing due to the emergence of new targeted therapies for the treatment of different molecular subtypes. Some biomarkers are described as potential molecular targets different from classic androgen receptors (AR). Approximately 20–25% of mCRPCs have somatic or germline alterations in DNA repair genes involved in homologous recombination. These subtypes are usually associated with more aggressive disease. Inhibitors of the enzyme poly ADP ribose polymerase (PARPi) have demonstrated an important benefit in the treatment of these subtypes of tumors. However, tumors that resistant to PARPi and wildtype BRCA tumors do not benefit from these therapies. Recent studies are exploring drug combinations with phosphatidylinositol-3-kinase (PI3K) or protein kinase B (AKT) inhibitors, as mechanisms to overcome resistance or to induce BRCAness and synthetic lethality. This article reviews various different novel strategies to improve outcomes in patients with prostate cancer.

scholarly journals Bone Health and Bone-Targeted Therapies for Prostate Cancer: ASCO Endorsement of a Cancer Care Ontario Guideline

2020 ◽  
Vol 38 (15) ◽  
pp. 1736-1743 ◽  
Author(s):  
Philip J. Saylor ◽  
R. Bryan Rumble ◽  
Scott Tagawa ◽  
James A. Eastham ◽  
Antonio Finelli ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Targeted Therapies ◽  
Bone Health ◽  
Cancer Care ◽  
Expert Panel ◽  
Scientific Evidence ◽  
Professional Organizations ◽  
Castration Resistant Prostate Cancer ◽  
Castration Resistant ◽  
Evidence Based Care

PURPOSE In 2017, Cancer Care Ontario’s Program in Evidence-Based Care released the Bone Health and Bone-Targeted Therapies for Prostate Cancer guideline. This guideline included recommendations across a relatively broad clinical spectrum within prostate cancer. Topics addressed ranged from management of osteoporotic fracture risk in nonmetastatic disease to management of men with castration-resistant prostate cancer metastatic to bone. ASCO has a policy and set of procedures for endorsing clinical practice guidelines that have been developed by other professional organizations. METHODS The Bone Health and Bone-Targeted Therapies for Prostate Cancer guideline was reviewed for developmental rigor by methodologists. An ASCO Expert Panel then reviewed the content and the recommendations. RESULTS The ASCO Expert Panel determined that the recommendations from the Bone Health and Bone-Targeted Therapies for Prostate Cancer guideline were clear, thorough, and based on the most relevant scientific evidence. ASCO wholly endorses the Bone Health and Bone-Targeted Therapies for Prostate Cancer guideline. RECOMMENDATIONS The ASCO Expert Panel endorses all the original guideline recommendations as written and offers a series of discussion points to guide practice for clinicians as they manage bone-related risks within this patient population.

Castration-Resistant Prostate Cancer: Targeted Therapies

Chemotherapy ◽  
2011 ◽  
Vol 57 (2) ◽  
pp. 115-127 ◽  
Author(s):  
S. Leo ◽  
C. Accettura ◽  
V. Lorusso
Keyword(s):  
Prostate Cancer ◽  
Targeted Therapies ◽  
Castration Resistant Prostate Cancer ◽  
Castration Resistant

scholarly journals Androgen receptor targeted therapies in metastatic castration-resistant prostate cancer – The urologists' perspective

2017 ◽  
Vol 28 (4) ◽  
pp. 190-196
Author(s):  
Jo-Lynn Tan ◽  
Niranjan Sathianathen ◽  
Nicolas Geurts ◽  
Rajesh Nair ◽  
Declan G. Murphy ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Androgen Receptor ◽  
Targeted Therapies ◽  
Castration Resistant Prostate Cancer ◽  
Castration Resistant

scholarly journals Emerging Targeted Therapies for Castration-Resistant Prostate Cancer

2012 ◽  
Vol 3 ◽  
Author(s):  
Vincenzo Adamo ◽  
Laura Noto ◽  
Tindara Franchina ◽  
Giuseppe Chiofalo ◽  
Maria Picciotto ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Targeted Therapies ◽  
Castration Resistant Prostate Cancer ◽  
Castration Resistant
Sign in / Sign up

Export Citation Format

Share Document